Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Prestes
Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective
BMC Health Services Research
Health Policy
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
Pdb78 - Economic Evaluation of Dapagliflozin as Add-On to Metformin for T2dm Treatment in the Israeli Healthcare Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Dapagliflozin (Forxiga®) Versus Glipizide as Add-On Therapies in Type 2 Diabetes Mellitus (T2dm); An Update of the Cost-Effectiveness Based on Long-Term Clinical Evidence From Uk NHS Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-On to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus (T2dm)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of First-Line Versus Delayed Use of Combination Dapagliflozin and Metformin in Patients With Type 2 Diabetes
Scientific Reports
Multidisciplinary
